Skip to content
Back to the Guavy Wire
Stocks

BMS Sues Amgen Over Proposed Opdivo Biosimilar

Instruments
AMGN
Share

Bristol Myers Squibb (BMS) and Ono Pharmaceutical have filed a lawsuit against Amgen in Delaware federal court, seeking to block the approval of Amgen's proposed biosimilar for Opdivo, a cancer immunotherapy drug.

The Wire

Read the full article for free.

A free account opens the rest of this article, how it scored, and the full Wire stream. No card required.

No spam. Unsubscribe anytime.